Based on the FDA’s written comments, United Therapeutics Corporation (NASDAQ: UTHR) has decided to discontinue the development of Trevyent.
- Trevyent is a drug-device combination product that combines two-day, single-use, disposable PatchPump technology with treprostinil for the subcutaneous treatment of pulmonary arterial hypertension.
- The comments followed a meeting to discuss the company’s planned resubmission of its marketing application for Trevyent in light of a Complete Response Letter issued in April last year.
- The FDA’s comments indicated that United Therapeutics would need to redesign the product to improve pump accuracy in certain respects and conduct a clinical study of the redesigned product.
- Thus, the company will stop the development of Trevyent as it is no longer considered commercially reasonable.
- Initially, the company submitted Trevyent application in September 2019.
- The company expects to incur an impairment charge of roughly $107.3 million during the first quarter of 2021.
- Price Action: UTHR shares are down 0.35% at $166 in premarket trading on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
